New Products

Home » New Products

 

NOW AVAILABLE

25-OH Vitamin D ELISA:

 
Click to download PDF copy
  • requires only 25μL Serum/plasma sample
  • internal kit controls included
  • single-breakable wells
  • only 105 min. incubation time
  • No extraction step required! (active)
  • Recognizes both isomers Vitamin D2 and D3
  • CE Marked
 
 
 

 

Aldosterone ELISA:

 
Click to download PDF copy
  • requires only 50μL Serum/plasma sample
  • internal kit controls included
  • single-breakable wells
  • very simple assay procedure
  • only 60 min. incubation time (without shaking) (active)
  • Very good correlation to RIA and LC-MS
  • CE Marked
 
 

RENIN (active) ELISA:

 

 

Click to download PDF copy
  • requires only 50μL Serum/plasma sample
  • internal kit controls included
  • single-breakable wells
  • only 195 min. incubation time
  • much faster assay procedure than for PRA
  • CE Marked
 

 

ALSO AVAILABLE

 

DRG Saliva ELISAS:

 

 

Click to download PDF copy

Clear advantages:

  • Higher diagnostic relevance with reproducible and reliable results compared to serum analytics
  • Measurement of free (unbound) fraction of steroids
  • Non-invasive, easy sampling particularly for babies and children
  • Simple and patient-friendly measurement of hormone profiles (Diurnal-, monthly profiles)
  • Measurement of steroids in veterinary saliva samples is possible without any further pre-treatme

SLV-Tests

 

 

 

NEW Tumor Marker ELISA (RUO) Kits:

Click to download PDF copy
  • Afamin
  • Cripto-1
  • CTGF
  • CYR 61 
  • L1-CAM
  • NOV (CCN3)
  • Free PSA
  • PSA total
  • TM-CA 15-3
  • TM-CA125
  • TM-CA 19-9
  • TM-CA 72-4
  • TM-CYFRA 21-1
 
 

 


MORE ELISA (RUO) Kits:

 
  • Anti-Amyloid (human) beta Auto-Ab
  • Amyloid (human) beta 1-40
  • Fasciola Hepatica IgG  
  • Hepcidin 25 (c-terminal) (U.S. Patents: 7,320,894; 7,411,048; 7,998,691)
 

 

AVAILABLE SOON

 

NEW  ELISA Kits In Development:

 
  
  • Estrone Salivary ELISA
  • ER60 (male fertility) ELISA Kit
 
Return to Home Page   |   Return to the Top of this Page